FDA 483 - Sato Pharmaceutical Co., Ltd. - November 13, 2025

The provided document details the foundational principles and regulatory framework for an FDA Form 483, which is issued to companies following an inspection. This form's primary purpose is to report observed objectionable conditions and practices, thereby assisting inspected firms in achieving compliance with the Acts and regulations enforced by the Food and Drug Administration. The legal basis for these reports is rooted in FD&C Act Section 704(b). This section mandates that, upon completion of an inspection, the officer provide a written report outlining conditions or practices that suggest a product (food, drug, device, or cosmetic) may be adulterated, decomposed, or has been prepared, packed, or held under insanitary conditions that could lead to contamination or render it injurious to health. The intent is to inform companies of findings requiring corrective actions to ensure public health and safety. However, the provided text constitutes a general explanation of the FDA 483 form and its statutory backing. It does not include specific details such as a company name, actual inspection dates, concrete main violations or issues identified during a particular inspection, or any specific required actions tailored to an individual firm.